Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135701 | 0.86 | HTR2A (0.41) | PDE4DCHRM4PDE4APDE4BPDE4C | |
| SCHEMBL16135557 | 0.84 | PDE4A (0.48) | PDE4DCHRM4PDE4APDE4BPDE4C | |
| SCHEMBL16135550 | 0.83 | CHRM4 (0.46) | CHRM4MAPK8WDR5PDE10ALMNA | |
| SCHEMBL16135540 | 0.82 | PDE4A (0.46) | PDE4DPDE4APDE4BPDE4CWDR5 | |
| SCHEMBL16135629 | 0.81 | PDE4A (0.48) | PDE4DPDE4APDE4BPDE4CWDR5 | |
| SCHEMBL16135592 | 0.81 | WDR5 (0.46) | PDE4DCHRM4PDE4APDE4BPDE4C | |
| SCHEMBL16135584 | 0.81 | WDR5 (0.46) | PDE4DCHRM4PDE4APDE4BPDE4C | |
| SCHEMBL16135583 | 0.80 | PDE4A (0.41) | PDE4DCHRM4PDE4APDE4BPDE4C | |
| SCHEMBL16135603 | 0.79 | CHRM4 (0.42) | PDE4DCHRM4PDE4APDE4BPDE4C | |
| SCHEMBL16135628 | 0.77 | HDAC1 (0.41) | PDE4DCHRM4PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970124-B1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | UNIV LELAND STANFORD JUNIOR (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-11-09 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670162-B2 | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-21 | — | — | US | disclosed |
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-21 | — | — | US | disclosed |
| WO-2014160185-A2 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107996-A1 | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, SHMT2 | PDE4D 918/4885CHRM4 4416/4885PDE4A 807/4885 |
| US-20170320828-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | ALDH2, ALDH5A1, DLD | PDE4D 636/4885CHRM4 4082/4885PDE4A 686/4885 |
| US-10227304-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | ALDH2, ALDH5A1, DLD | PDE4D 636/4885CHRM4 4082/4885PDE4A 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.